Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV SBC-103 in MPS IIIB (Sanfilippo B)
NL-OMON43718Phase 2Withdrawn
- Sponsor
- Alexion Pharmaceuticals
- Start
- Aug 2015
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lesinidase alfa in mucopolysaccharidosis type IIIB, sponsored by Alexion Pharmaceuticals. Primary endpoints: Safety and tolerability of SBC-103, Clinical laboratory and CSF safety assessments and 5 more. Planned start Aug 2015; status: withdrawn.
02
Drugs
lesinidase alfa
03
Conditions
mucopolysaccharidosis type IIIB
Beyond the preview
Go deeper on NL-OMON43718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43718.